Skip to main content

Table 1 Summary of the average (CV%) pharmacokinetic parameters from post-hoc bayesian estimates following protein i.v. injection in juvenile pigs

From: Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin

Form of protein

n

K (1/h)

K12 (1/h)

K21 (1/h)

Vc (L)

Thalf (h)

Vehicle (unit/mL)

BChE/hSA produced in vitro

2

0.0579 (0.0)

0.0993 (100)

0.103 (99.9)

0.581 (0.0)

32.4 (29.8)

1.83 (0.0)

BChE produced transgenically (>70% tetramer)

4

0.689 (28.4)

0.553 (18.4)

0.592 (0.000845)

0.120 (42.9)

2.74 (12.6)

1.45 (0.0)

  1. CV%: The intersubject variation, reported as a percentage (%) of coefficient of variation;
  2. K: The elimination rate constant from the central compartment;
  3. K12: The rate constant of the protein from the central to the first peripheral compartment;
  4. K21: The rate constant of the protein from the first peripheral to the central compartment;
  5. Vc: The volume of the central compartment following i.v. administration;
  6. Thalf: The apparent terminal elimination half-life;
  7. Vehicle: The response detected by the analytical assay that is considered as background activity in untreated juvenile pig plasma, not related to the administration of the protein, using 720 units = 1 mg purified plasma huBChE and assay conditions as described in. [29].
Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us